Doxorubicin cardiomyopathy carries an approximately 50% mortality once congestive heart failure develops, with no effective treatments currently available.
No takes yet. Share an insight, caveat, or question.
High mortality once HF develops in doxorubicin cardiomyopathy warrants close surveillance; leaves open need for effective therapies.
Chatterjee et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: